Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin
Status
Conditions
Treatments
Details and patient eligibility
About
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.
Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide.
The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future
Full description
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.
The Infectious Diseases Society of America recommends the use of daptomycin 6 mg / kg / day in the second-line treatment of IOA on staphylococcal but also enterococcal prostheses, as an alternative to vancomycin and linezolid.
In case of renal failure, daptomycin is often considered as a good therapeutic alternative to glycopeptides.
Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. Although a large proportion of cases have been reported in patients receiving daptomycin in unapproved indications, the use of daptomycin in authorized indications has also been associated with this risk.
The dosage of daptomycin makes it possible to evaluate its effectiveness and prevent the occurrence of a overdose, provider of side effects.
The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (BJI/PJI)
Exclusion criteria
Trial design
20 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Eugénie Mabrut, CRA; Tristan Ferry, Md,PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal